| Assay ID | Title | Year | Journal | Article |
|---|
| AID1822146 | Intrinsic clearance in human liver microsomes at 1 uM measured upto 60 mins by LC-MS/MS-11 analysis | | | |
| AID1822063 | Agonist activity at PPARgamma (unknown origin) assessed as maximal activation at 10 nM relative to control | | | |
| AID1759582 | Inhibition of NLRP3 in mouse J774A.1 cells infected with FLA-ST assessed as inhibition of LPS- induced IL-1beta production by ELISA | 2021 | European journal of medicinal chemistry, Jul-05, Volume: 219 | Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. |
| AID1822055 | Agonist activity at PPARalpha (unknown origin) | | | |
| AID1511004 | Hepatoprotective activity in Sprague-Dawley rat assessed as reduction in ANIT-stimulated inflammatory score at 30 mg/kg, ig administered for 8 days by hematoxylin and eosin staining based mopho-metric analysis | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1773583 | Agonist activity at human PPARalpha transfected in human HepG2 cells assessed as maximal activation incubated for 18 hrs by Renilla/Firefly dual-luciferase reporter assay relative to GW7647 | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. |
| AID1773582 | Agonist activity at human PPARalpha transfected in human HepG2 cells incubated for 18 hrs by Renilla/Firefly dual-luciferase reporter assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. |
| AID1510961 | Selectivity index, ratio of EC50 of PPARgamma (unknown origin) to EC50 of PPARdelta (unknown origin) | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1822057 | Agonist activity at PPARgamma (unknown origin) | | | |
| AID1753552 | Agonist activity at human Gal4 fused PPARgamma LBD expressed in COS-7 cells incubated for 24 hrs by firefly luciferase reporter gene assay | 2021 | European journal of medicinal chemistry, Jun-05, Volume: 218 | Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms. |
| AID1511005 | Hepatoprotective activity in Sprague-Dawley rat assessed as reduction in ANIT-stimulated fibrosis area at 30 mg/kg, ig administered for 8 days by hematoxylin and eosin staining based mopho-metric analysis | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1773585 | Agonist activity at human PPARgamma transfected in human HEK293 cells assessed as maximal activation incubated for 18 hrs by Renilla/Firefly dual-luciferase reporter assay relative to rosiglitazone | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. |
| AID1822145 | Microsomal stability in human liver microsomes assessed as terminal elimination half life at 1 uM measured upto 60 mins by LC-MS/MS-11 analysis | | | |
| AID1510960 | Selectivity index, ratio of EC50 of PPARgamma (unknown origin) to EC50 of PPARalpha (unknown origin) | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1510959 | Agonist activity at PPARgamma (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay relative to Troglitazone | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1753551 | Agonist activity at human Gal4 fused PPARdelta LBD expressed in COS-7 cells incubated for 24 hrs by firefly luciferase reporter gene assay | 2021 | European journal of medicinal chemistry, Jun-05, Volume: 218 | Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms. |
| AID1510957 | Agonist activity at PPARalpha (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay relative to GW7647 | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1510958 | Agonist activity at PPARbeta (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay relative to L-165,041 | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1546882 | Agonist activity at PPARalpha (unknown origin) | 2020 | Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
| The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. |
| AID1822056 | Agonist activity at PPARdelta (unknown origin) | | | |
| AID1822062 | Agonist activity at PPARdelta (unknown origin) assessed as maximal activation at 10 nM relative to control | | | |
| AID1510955 | Agonist activity at PPARbeta (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1759587 | Selectivity index, ratio of TC50 for cytotoxicity against human HEK293T cells to IC50 for inhibition of NLRP3 in mouse J774A.1 cells | 2021 | European journal of medicinal chemistry, Jul-05, Volume: 219 | Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. |
| AID1510956 | Agonist activity at PPARgamma (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1546884 | Agonist activity at PPARdelta (unknown origin) | 2020 | Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
| The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. |
| AID1773587 | Agonist activity at human PPARdelta transfected in human HEK293 cells assessed as maximal activation incubated for 18 hrs by Renilla/Firefly dual-luciferase reporter assay relative to GW0742 | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. |
| AID1773586 | Agonist activity at human PPARdelta transfected in human HEK293 cells incubated for 18 hrs by Renilla/Firefly dual-luciferase reporter assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. |
| AID1759586 | Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 24 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Jul-05, Volume: 219 | Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. |
| AID1779666 | Agonist activity at human BLT2 overexpressed in CHO-K1 cells assessed as accumulation of inositol monophosphate measured after 90 mins by HTRF assay | 2021 | ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
| Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening. |
| AID1510954 | Agonist activity at PPARalpha (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1753550 | Agonist activity at human Gal4 fused PPARalpha LBD expressed in COS-7 cells incubated for 24 hrs by firefly luciferase reporter gene assay | 2021 | European journal of medicinal chemistry, Jun-05, Volume: 218 | Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms. |
| AID1510996 | Hepatoprotective activity in Sprague-Dawley rat assessed as reduction in ANIT-stimulated total bilirubin level at 30 mg/kg, ig administered for 8 days by biochemical analysis | 2019 | ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
| Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis. |
| AID1822061 | Agonist activity at PPARalpha (unknown origin) assessed as maximal activation at 10 nM relative to control | | | |
| AID1773584 | Agonist activity at human PPARgamma transfected in human HEK293 cells incubated for 18 hrs by Renilla/Firefly dual-luciferase reporter assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |